ReviewJournal of pharmacy & bioallied sciences2026
Neuroprotectants: The Next Frontier in Neurology.
Review in Journal of pharmacy & bioallied sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Synergistic Neuroprotective Effect of Honokiol and Magnolol Against Amyloid-β and MPPInternational journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroprotectants are drugs or substances that help protect the brain and nerves from damage caused by injuries or diseases like stroke, Alzheimer's disease, and Parkinson's disease. This review looks at different types of neuroprotective agents, including those that reduce inflammation, prevent cell death, or improve blood flow to the brain. While many of these substances show good results in lab studies, only a few have been successful in human trials. This is often due to problems like delayed treatment, difficulty reaching the brain, and differences between patients. The review also discusses future clinical trials and how new technologies and targeted treatments may improve outcomes. Understanding how these agents work and how to test them better could lead to more effective treatments for brain disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.